Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has released its unaudited financial results for Q1 FY27, showing a 2% YoY growth in revenue to INR 1,898 million, but a 7% sequential decline. The company's performance is affected by the global economic challenges and volatility in energy and raw material prices.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has submitted a daily report under Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 18, 2026, through the stock exchanges mechanism.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has submitted a daily report under Regulation 18(i) of the Buyback Regulations regarding the equity shares bought back on August 17, 2026, through the stock exchange mechanism.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has submitted a daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought back on August 14, 2026, through the stock exchange mechanism.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has released the audio recording of its earnings call held on August 12, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced a board resolution for a buyback of up to 10% of its paid-up equity share capital and free reserves through the open market route. The buyback will be at a price not exceeding ₹ 500 per equity share, and the maximum buyback size is ₹ 697,000,000. The company will utilize at least 75% of the buyback size towards the buyback, and at least 40% of the buyback size will be utilized within the initial half of the offer period.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced a buyback of its equity shares from the open market through stock exchanges under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended. The buyback will open on August 14, 2026, and will end on the earlier of sixty-six working days, completion of the buyback, or a date determined by the Board.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has published its unaudited consolidated financial results for the quarter ended June 30, 2026, in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited announced its unaudited financial results for the first quarter ended June 2026, with revenue increasing by 2% year-on-year to ₹1,898 million and EBITDA margin standing at 27%. Profit after tax de-grew by 5% to ₹386 million.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced its earnings presentation for the quarter ended June 30, 2026, with revenue growing by 2% YoY to ₹1,859 crore, EBITDA de-growth of 10% to ₹510 million, and PAT decreasing to ₹386 million. The human nutrition segment contributed around 60% to the total revenue, de-grew by 7% YoY, and de-grew by 11% sequentially. The animal nutrition segment contributed around 13% to the total revenue, de-grew by 3% YoY, and de-grew by 5% sequentially.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has approved the buyback of up to 1,394,000 equity shares at a price not exceeding ₹500 per share, representing 1.24% of the existing paid-up equity capital. The company has also approved the acquisition of the remaining 4.28% stake in JC Biotech Private Limited and infusion of up to ₹20 million in Advanced Nutrazyme Private Limited.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd approved the acquisition of the remaining stake of 4.28% Equity Shares from the other existing Shareholders of JC Biotech Private Limited and approved infusion of additional funds not exceeding ₹ 20 million in Advanced Nutrazyme Private Limited. The company also approved the buyback of fully paid-up equity shares having a face value of ₹ 2/- each at a price not exceeding ₹ 500/- per equity share.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced unaudited financial results for the quarter ended June 30, 2026, and approved a buyback of up to 1,394,000 equity shares at a maximum price of ₹500 per share, and also approved the acquisition of the remaining stake of 4.28% in JC Biotech Private Limited and infusion of additional funds in Advanced Nutrazyme Private Limited.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd approved un-audited financial results for Q2 2026, buyback of equity shares, and acquisition of remaining stake in JC Biotech Private Limited.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd will host a conference call to discuss its un-audited financial results for the quarter ended June 30, 2026, on August 12, 2026.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director for five years, effective from April 01, 2027 to March 31, 2032, and the appointment of Mr. Pradip Bhailal Shah as an Independent Director for five consecutive years.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has announced the voting results of its 37th Annual General Meeting, where all resolutions were passed with the requisite majority. The company received 99.04% votes in favour of the resolutions, with 0.96% votes invalid.

Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has scheduled a board meeting on August 8, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, and propose a buyback of equity shares.

Advanced Enzyme Technologies Ltd

The 37th Annual General Meeting (AGM) of Advanced Enzyme Technologies Limited was held on July 31, 2026, through video conference, with 106 members present. The meeting approved various resolutions, including the appointment of a director, reappointment of statutory auditors, and approval of related party transactions.